All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2021; the latest 2023-03-17.
From the record
Xeris Biopharma Holdings, Inc.'s filings since 2021 show 1 warning event: an auditor change (8-K item 4.01, the latest 2023-03-17) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+70.7% a year over 6 filed years; profitable in 1 of 6.
From the record
Xeris Biopharma Holdings, Inc.'s 6 filed years say what it did: revenue went from $20 million in fiscal 2020 to $292 million in fiscal 2025, up 70.7% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 1 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Xeris Biopharma Holdings, Inc.'s shareholder treatment is put at 6.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 32% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE 4%: 4¢ of profit per shareholder dollar. Leverage 96%: owes 96¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Xeris Biopharma Holdings, Inc. earned about 4 cents of profit for every dollar of shareholders' money. Leverage: it owed about 96 cents per dollar of assets, and net share issuance: its share count grew 17.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 25% of 315 in its family; net margin 0.2%.
From the record
Xeris Biopharma Holdings, Inc.'s standing among 315 graded names in its industry family: revenue of $292 million in fiscal 2025 ranks in the top 24% by size; a net margin of 0.2% ranks in the top 24%; revenue growth of 38.3% a year over the last 3 filed years ranks in the top 27% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 33% of 315 in its family for leadership; chief executive since 2024.
From the record
Xeris Biopharma Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Shannon, John Patrick Jr (Chief Executive Officer and Chairman of the Board, as filed), filing under that title since 2024-08-02, 2.3 years (bottom 25% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 37%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 37%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 33% of 273 in its family for room to expand.
From the record
Xeris Biopharma Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $111 million against debt of $220 million leaves -28.5% of its assets as net cash, bottom 5% of its family; cash from operations less capital spending is 9.8% of revenue (top 21%); research spending of 10.7% of revenue (bottom 15%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 37% of 306 in its family for growth drivers.
From the record
Xeris Biopharma Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 38.3% a year over the last three filed years against 70.7% over all 6, slowing (bottom 18% of its family); the newest year grew 43.8% (top 28%); research spending grew 14.1% a year (top 32%); capital spending grew 188% a year (top 3%) (its annual reports). Xeris Biopharma Holdings, Inc. reported 5 product lines in fiscal 2025: Recorlev at $139 million (48%), Gvoke at $94 million (32%), Keveyis at $48 million (16%), and 2 more; 3 of 4 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 30% of 233 in its family for expectations against reality.
From the record
Xeris Biopharma Holdings, Inc.'s newest year against its own record: revenue of $292 million in fiscal 2025 came in 5.9% above the $276 million its prior three years' pace pointed to (top 37% of its family); net income of $554 thousand against a prior three-year average of $71 million (top 16%); a net margin of 0.2% against -50.3% before (top 37%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made